Plain-English translation of NCT06449781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new radioactive treatment called 177Lu-PSMA, given as a single injection, to see if it can help prevent prostate cancer from returning in men with aggressive prostate cancer who have already completed surgery, radiation, and hormone therapy. About 200 men will participate: some will receive the medication along with their regular hormone therapy, while others will continue with hormone therapy alone. The study will follow everyone for 5 years to see who stays cancer-free.
High-risk prostate cancer can come back even after surgery and radiation, and doctors are looking for ways to reduce that risk. This medication targets cancer cells using a radioactive substance, and researchers want to know if giving it right after standard treatment can help prevent the cancer from spreading.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will come to the hospital for one day to receive either the radioactive injection or continue with your regular hormone therapy only (decided randomly). After that single treatment day, you will have follow-up visits and scans over the next 5 years to check if your cancer stays under control. The study team will monitor your health and watch for any side effects during regular check-ups.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Poland